即使母亲接种了疫苗,婴儿在出生时安全地获得不受niresevimab感染的强有力的RSV保护。 Infants safely gain strong RSV protection from nirsevimab at birth, even if mothers were vaccinated.

在IDWeek提交的一份新研究报告证实,婴儿出生后可以安全地接受RSV抗体喷射疫苗,即使其母亲在怀孕期间接种了疫苗。 A new study presented at IDWeek confirms that infants can safely receive the RSV antibody shot nirsevimab after birth, even if their mothers were vaccinated during pregnancy. 研究人员对181对母婴儿进行了分析,发现所有婴儿体内的RSV抗体水平都很高,没有严重的副作用报告。 Analyzing 181 mother-infant pairs, researchers found high RSV antibody levels in all babies, with no serious side effects reported. 这一镜头大大加强了保护 -- -- 未接种疫苗的母亲婴儿的保护增加了25倍,接种疫苗的母亲婴儿的保护增加了3倍以上。 The shot significantly boosted protection—25-fold in unvaccinated mothers’ babies versus over three-fold in vaccinated mothers’ babies. 这些发现支持将母婴RSV预防策略结合起来,加强了CDC的建议. Findings support combining maternal and infant RSV prevention strategies, reinforcing CDC recommendations. 这项研究正在进行中,计划对一年多来母乳中的抗体耐久性和水平进行监测。 The study is ongoing, with plans to monitor antibody durability and levels in breast milk over a year.